Recursion Pharmaceuticals, Inc. (RXRX) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Recursion's earnings call presented a mixed but generally positive outlook. The company showcased strong financial health, with significant cash reserves and reduced cash burn projections. Strategic partnerships with major players like Sanofi and Roche are advancing, and the company is leveraging AI for drug development. Despite some uncertainties in clinical trials and platform integration, the optimistic guidance and potential milestone achievements suggest a positive sentiment. The market cap suggests moderate volatility, supporting a positive stock price movement prediction in the 2% to 8% range.
Key Financial Performance
Cash Balance $533 million at the end of the quarter, with a commitment to manage expenses efficiently. This represents a 35% reduction in expected cash burn by 2026 compared to 2024 levels. Reasons for change include efficient expense management and inflows such as a $29 million R&D tax credit and milestone payments from partnerships.
Cash Burn Expected to be below $390 million in 2026, a 35% reduction from 2024 levels. This reduction is attributed to efficient expense management and strategic financial planning.
R&D Tax Credit $29 million received as a U.K. tax credit during the quarter. Future credits will be smaller due to legislative changes.
Partnership Inflows Projected to exceed $100 million by the end of 2026. This includes milestone payments from partnerships such as Sanofi.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Recursion OS 2.0: Integration of components from Exscientia and Recursion to create an end-to-end capability from target discovery to clinical trial simulation. Incorporation of Boltz-2 technology for protein folding and ligand binding predictions, achieving 1,000-fold less compute requirements.
ClinTech platform: Deployed across all programs, enabling patient data integration, target identification, patient stratification, and clinical trial simulation. Achieved 50% faster enrollment projections and 30% improved dose optimization for patients.
Partnerships: Collaborations with Roche, Sanofi, Bayer, and Merck KgAa. Achieved fourth milestone in Sanofi partnership and developed phenomaps with Roche for neuroscience and GI-Onc applications. Potential for over $100 million in partnership milestones by 2026.
Operational efficiencies: Reduced cash burn by 35% since 2024, with a projected burn below $390 million in 2026. Strong cash balance of $533 million and expected cash runway through Q4 2027.
Strategic shifts: Focus on differentiated, high-quality programs leveraging Recursion OS 2.0 and ClinTech platform. Emphasis on integrating AI and multimodal maps for drug discovery and clinical development.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Changes Impacting R&D Tax Credits: The company highlighted that changes in U.K. legislation will reduce the size of R&D tax credits they receive in the future, which could impact cash inflows.
Challenges in Targeting CDK7: CDK7 has been an important target but has faced challenges with permeability, efflux, and absorption, which the company is attempting to address through AI-driven molecule design.
RBM39 Development Risks: RBM39 is a first-in-class target with potential challenges in identifying the right patient populations and ensuring effective degradation mechanisms for solid tumors.
Dependence on Partnerships: The company relies heavily on partnerships with Roche, Sanofi, Bayer, and Merck KgAa for milestones and funding, which could pose risks if partnerships do not progress as planned.
Cash Burn and Financial Sustainability: Despite reducing cash burn by 35% since 2024, the company still projects significant cash burn through 2026, with a runway only through Q4 2027, excluding additional partner inflows or financing.
Clinical Trial Execution Risks: While the company is leveraging AI to improve trial design and recruitment, there are inherent risks in achieving faster enrollment and ensuring trial success.
Platform Integration Challenges: The integration of Exscientia's platform into Recursion OS 2.0 is complex and may face challenges in achieving seamless functionality and delivering expected efficiencies.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue and Partnership Inflows: The company projects over $100 million in partnership inflows by the end of 2026. This includes milestone payments from partnerships with companies like Sanofi, Roche, Bayer, and Merck KgAa.
Cash Burn and Financial Management: The company expects to manage its cash burn below $390 million in 2026, with a cash runway projected through Q4 2027. This projection excludes additional partner inflows or financing.
Clinical Trial Advancements: Recursion anticipates multiple clinical trial readouts over the next 18 months, including:
- FAP and CDK7 readouts in the second half of 2025.
- RBM39 early safety and PK data in the first half of 2026.
- MALT1 and ENPP1 program initiation in the second half of 2026.
Platform Development and Efficiency: The Recursion OS 2.0 platform is expected to enhance drug discovery and clinical trial efficiency. The company aims to bring medicines to the clinic faster and at lower costs, leveraging AI-powered tools and iterative learning cycles.
Partnership Milestones: The company achieved its fourth milestone in the Sanofi partnership and expects to achieve over $100 million in partnership milestones by the end of 2026.
Pipeline Expansion: The company plans to expand its internal pipeline with high-quality, differentiated programs, including oncology and rare disease targets. New programs will integrate advanced AI and machine learning tools from the Recursion OS 2.0 platform.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Is Boltz-2 the initiative with a major partner on foundational protein structure modeling mentioned earlier this year?
A:Yes, Boltz-2 is the partnership mentioned earlier this year at JPMorgan.
Q:Why choose open source for Boltz-2 instead of keeping it internal?
A:The company believes in commoditizing certain technologies to ensure broad access while keeping proprietary tools that provide a differentiated advantage internal.
Q:Are you still building proprietary models?
A:Yes, the company is leveraging Boltz-2 models internally and training them on larger proprietary datasets for an internal advantage.
Q:What standard of care is allowed in the CDK7 combo expansion cohort in ovarian cancer trials?
A:The standard of care includes single-agent chemotherapy plus bevacizumab. Median PFS is about 6.7 months, and median OS is about 14 to 22 months.
Q:Do you expect multiomic profiling data for REC-1245 to dictate patient enrollment in future studies?
A:Yes, the data will help select patients with certain biomarkers and guide future studies. The approach targets a broad set of genomically unstable tumor types.
Q:What differentiates RBM39 from other CDK targeting assets?
A:RBM39 is not a kinase, unlike CDK12, and offers selectivity for DDR modulation without the challenges of kinase homology.
Q:What is the threshold for success in the upcoming FAP data readout?
A:The company seeks meaningful improvement in polyp burden reduction beyond the 20%-30% seen with off-label treatments like Celecoxib. Broader patient data later this year will guide further steps.
Q:What was achieved to merit the $7 million milestone under the Sanofi collaboration?
A:The milestone was achieved for successfully targeting a challenging immunology target, focusing on lead series development.
Q:What visibility do you have on the potential $100 million in milestones by 2026?
A:The guidance is based on existing partnerships and programs, with milestones probability-weighted. New business development is not included in the estimate.
Q:How does the company plan to achieve its Q4 2027 cash runway guidance?
A:The company focuses on cash-based operating expenses, efficient spending, and executing existing partnerships. Multiple scenarios support achieving the guidance.
Q:What ambitious initiatives reflect the company's next level of thinking?
A:The company is advancing towards a 'virtual cell' model, integrating multiple data layers. It also has a Frontier Research Group exploring high-risk, high-reward areas like automated medicine discovery.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the $7 million milestone target under the Sanofi collaboration, citing confidentiality. Additionally, they did not provide clear thresholds for FAP data approval and uptake, deferring to future regulatory discussions.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI chemistry
Bayer Merck
Boltz
CDK panel
CFO President
Chief
MOA
Merck KgAa
OS platform
RD
Recursion OS
absorption
approach
area value
case
challenge
combination arm
component Recursion
degrader
design
dose escalation
efflux
et cetera
expertise
field
hand side
inference
line
module
monotherapy dose
order
others
pathway
permeability
perturbation
population
prediction
replication stress
target
understanding
RXRX Transcript
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Recursion Pharmaceuticals, Inc. (RXRX) Q1 2026 Earnings Call Transcript
Unknown5-6
The earnings call summary highlights a commitment to AI-driven innovation and financial discipline, which are positives, but lacks specific financial details such as revenue or margin figures. The Q&A section does not provide additional insights, and risks related to AI development and regulatory compliance are noted. With a market cap of approximately $1.8 billion, the absence of explicit financial metrics and shareholder return plans suggests a neutral stock price movement in the short term.
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Neutral4-17
RXRX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
